tradingkey.logo
tradingkey.logo
Buscar

Beta Bionics Inc

BBNX
Añadir a la lista de seguimiento
16.760USD
+0.060+0.36%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
746.85MCap. mercado
PérdidaP/E TTM

Más Datos de Beta Bionics Inc Compañía

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Información de Beta Bionics Inc

Símbolo de cotizaciónBBNX
Nombre de la empresaBeta Bionics Inc
Fecha de salida a bolsaJan 30, 2025
Director ejecutivoSaint (Sean)
Número de empleados291
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección11 Hughes
CiudadIRVINE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92618
Teléfono19494277785
Sitio Webhttps://www.betabionics.com
Símbolo de cotizaciónBBNX
Fecha de salida a bolsaJan 30, 2025
Director ejecutivoSaint (Sean)

Ejecutivos de Beta Bionics Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
95.61K
-5.86%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
23.40K
-12.01%
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
23.40K
+63.96%
Mr. Sean Saint
Mr. Sean Saint
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.67K
-297.67%
Mr. Stephen Feider
Mr. Stephen Feider
Chief Financial Officer
Chief Financial Officer
3.18K
-210.20%
Mr. Michael (Mike) Mensinger
Mr. Michael (Mike) Mensinger
Chief Product Officer
Chief Product Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
95.61K
-5.86%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
23.40K
-12.01%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Beta Bionics Inc?

Los cinco principales accionistas de Beta Bionics Inc son: Dr. Steven Russell, M.D., Ph.D.

¿Cuántas instituciones poseen acciones de Beta Bionics Inc (BBNX)?

A fecha de 2026Q1, 264 instituciones poseen acciones de Beta Bionics Inc, con un valor de mercado combinado de aproximadamente 49.25M, lo que representa el 110.51% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2186348.00.

¿Cuál es la mayor fuente de ganancias de Beta Bionics Inc?

El 2026Q1, el segmento empresarial DME channel - iLet generó la ganancia más alta para Beta Bionics Inc, ascendiendo a 52.05M y representando el 51.92% de la ganancia total.